. Author manuscript; available in PMC: 2016 May 1.

Published in final edited form as: Ann Surg Oncol. 2014 Aug 14;22(5):1645–1650. doi: 10.1245/s10434-014-3976-z

TABLE 2.

Postoperative morbidity of CRS/HIPEC procedures (n = 1,019)

Variable	Time interval (days)	Non-DP (n = 956)	DP (n = 63)	p value
Minor morbidity^a [n (%)]	30	166 (17.4)	12 (19.1)	0.732
Minor morbidity^a [n (%)]	31–90	50 (5.2)	4 (6.4)	0.5702
Major morbidity^b [n (%)]	30	180 (18.8)	19 (30.2)	0.033
Major morbidity^b [n (%)]	31–90	58 (6.1)	5 (7.9)	0.584
Mortality [n (%)]	30	23 (2.6)	2 (3.2)	0.79
Mortality [n (%)]	31–90	16 (1.8)	1 (1.6)	1.00
Readmission [n (%)]	30	166 (21.1)	14 (29.2)	0.205
Readmission [n (%)]	31–90	243 (31.9)	18 (33.3)	0.881
Operation time [h; mean (SD)]		8.4 (3.1)	10.2 (3.2)	<0.0001
Hospitalization [days; mean (SD)]		14 (16)	22 (28)	<0.001
ICU stay [days; mean (SD)]		3.5 (9.4)	4.6 (7.9)	0.007
Estimated blood loss [ml; mean (SD)]		760 (775)	1,172 (701)	<0.001

CRS/HIPEC cytoreductive surgery with intraperitoneal hyperthermic chemotherapy, DP distal pancreatectomy, ICU intensive care unit, SD standard deviation

Clavien and Dindo Grade I–II

Clavien and Dindo Grade III–IV